| Literature DB >> 2413205 |
A Forbes, P J Johnson, R Williams.
Abstract
A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.Entities:
Mesh：
Substances：
Year: 1985 PMID： 2413205 PMCID： PMC1289947 DOI： 10.1177/014107688507801007
Source DB: PubMed Journal: J R Soc Med ISSN： 0141-0768 Impact factor: 5.344